MeMed's Groundbreaking Host-Response Diagnostic Hits Milestone with Over 100,000 Patient Tests Successfully Conducted
Located in the bustling hubs of both Massachusetts and Israel, pioneering startup MeMed has been making waves in the medical sphere. The company recently announced that its flagship diagnostic, MeMed BV®, has successfully conducted over 100,000 patient tests. This remarkable test has the ability to distinguish accurately between bacterial and viral infections in a speedy 15 minutes, granting it the status of a leader in the realm of host-response diagnostics. The groundbreaking number of tests conducted with MeMed BV® highlights the company’s dedication to advancing precision medicine and revolutionising infection management, and the adoption of the test in emergency medicine, urgent care, and hospital settings is demonstrative of a global shift towards host-response and precision diagnostics. An important collaborator in achieving this milestone has been Physicians Premier, an inventive and patient-focused emergency room network. The 100,000th patient test was performed at Physicians Premier’s Parkdale clinic in Corpus Christi, Texas, a moment that was commemorated by a jubilant celebration. The test’s 100,000-patient milestone indicates not only the industry’s move towards rapid host-response diagnostics, but also the global growth of the ingenious MeMed. The company intends to expand its notable impact through strategic partnerships, remaining focused on integrating high-throughput analysis into acute care settings and strengthening distribution across the US, Europe, and emerging markets. In the dawn of a new era of diagnostics, the future appears promising for the likes of MeMed BV®. As the company continues to align with healthcare providers and industry leaders, its vision of translating complex immune system signals into simple, actionable insights that transform disease management is becoming increasingly realised. In a world where precision medicine is fast becoming the norm, such innovation is not only welcomed, but needed.
- •MeMed BV Surpasses 100,000 Patient Tests, Underscoring Adoption of Rapid Host-Response Diagnostics venturebeat.com06-06-2025